A Blueprint for HIV Vaccine Discovery

Slides:



Advertisements
Similar presentations
Slide by eric martz, sept 2003 Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Daniel Calarese … Ian A. Wilson.
Advertisements

Lecture 18: Intracellular transport Flint et al., Chapter 12.
Structure of V3-containing HIV-1 gp120 core Huang, C. C., Tang, M., Zhang, M. Y., Majeed, S., Montabana, E., Stanfield, R. L., Dimitrov, D. S., Korber,
HIV & Influenza Figure 2 | Schematic diagram of HIV‑1 and influenza A virus. Both HIV-1 and influenza A virus are approximately 80–120 nm in diameter and.
The Quest for a Universal Flu Vaccine: Headless HA 2.0
Lymph node fine needle aspirates reveal germinal centers as predictors of HIV trimer-induced neutralizing antibodies Colin Havenar-Daughton Laboratory.
Chapter 43 The Immune System.
Glycoengineering With our versatile GlycoOpitimize ™ platform, Creative Biolabs provide antibody glycoengineering service for our clients all over the.
Predicting Vaccine Responsiveness
Volume 46, Issue 5, Pages e3 (May 2017)
Volume 156, Issue 4, Pages (February 2014)
Volume 8, Issue 12, Pages (December 2000)
Peter D. Kwong, John R. Mascola  Immunity 
HIV-1 Latency by Transition
Systems Vaccinology Immunity
M. Juliana McElrath, Barton F. Haynes  Immunity 
Volume 43, Issue 5, Pages (November 2015)
Influenza Vaccines: Challenges and Solutions
Christina Beatrice Karsten, Galit Alter  Cell Reports 
Volume 159, Issue 1, Pages (September 2014)
Volume 40, Issue 6, Pages (December 2010)
Volume 45, Issue 3, Pages (September 2016)
Antibodies and B Cell Memory in Viral Immunity
Volume 11, Issue 10, Pages (June 2015)
Solution Structure of a Cyanovirin-N:Manα1-2Manα Complex
Structure of V3-containing HIV-1 gp120 core
Lauren E. Higdon, Michael P. Cancro  Immunity 
Volume 46, Issue 6, Pages e6 (June 2017)
Volume 23, Issue 11, Pages (June 2018)
HIV and Tfh Cells: Circulating New Ideas to Identify and Protect
Model Building and Refinement of a Natively Glycosylated HIV-1 Env Protein by High- Resolution Cryoelectron Microscopy  Jeong Hyun Lee, Natalia de Val,
Volume 159, Issue 1, Pages (September 2014)
The Rational Design of an AIDS Vaccine
Volume 5, Issue 5, Pages (December 2013)
Dwelling on T Cell Fate Decisions
Nicki Harmon, Samantha Hurndon, & Zeb Russo
Germinal Center Selection and the Antibody Response to Influenza
Volume 14, Issue 11, Pages (March 2016)
Volume 16, Issue 9, Pages (August 2016)
Bali Pulendran, Rafi Ahmed  Cell 
Volume 43, Issue 6, Pages (December 2015)
CD4-Induced Activation in a Soluble HIV-1 Env Trimer
Volume 46, Issue 4, Pages (April 2017)
HIV-Host Interactions: Implications for Vaccine Design
Microsecond Dynamics and Network Analysis of the HIV-1 SOSIP Env Trimer Reveal Collective Behavior and Conserved Microdomains of the Glycan Shield  Thomas.
Designing Vaccines Based on Biology of Human Dendritic Cell Subsets
Adam S. Dingens, Hugh K. Haddox, Julie Overbaugh, Jesse D. Bloom 
Volume 22, Issue 2, Pages (August 2017)
Volume 22, Issue 2, Pages (February 2005)
Innate Immune Sensing of HIV-1 by Dendritic Cells
Michael S. Diamond, Theodore C. Pierson  Cell 
Jinal N. Bhiman, Penny L. Moore  Immunity 
Volume 2, Issue 4, Pages (October 2007)
How T Cells Earn the Follicular Rite of Passage
Golgi Feels DNA’s Pain Cell
Chemical Biology Approaches to Designing Defined Carbohydrate Vaccines
Volume 24, Issue 8, Pages (August 2016)
Bispecific Antibodies Against HIV
Volume 7, Issue 3, Pages (May 2014)
Volume 4, Issue 3, Pages (September 2008)
Wilbert Bitter, Coen Kuijl  Cell Host & Microbe 
Volume 49, Issue 2, Pages e8 (August 2018)
Guardians of the ERAD Galaxy
Sites and Stages of Autoreactive B Cell Activation and Regulation
HIV Broadly Neutralizing Antibodies: Taking Good Care Of The 98%
Volume 40, Issue 5, Pages (May 2014)
Volume 25, Issue 6, Pages e5 (June 2019)
Cure of HIV infection: Is the long wait over?
Follicular Helper T Cells: Lineage and Location
Novel pharmacological strategies to treat cystic fibrosis
Presentation transcript:

A Blueprint for HIV Vaccine Discovery Dennis R. Burton, Rafi Ahmed, Dan H. Barouch, Salvatore T. Butera, Shane Crotty, Adam Godzik, Daniel E. Kaufmann, M. Juliana McElrath, Michel C. Nussenzweig, Bali Pulendran, Chris N. Scanlan, William R. Schief, Guido Silvestri, Hendrik Streeck, Bruce D. Walker, Laura M. Walker, Andrew B. Ward, Ian A. Wilson, Richard Wyatt  Cell Host & Microbe  Volume 12, Issue 4, Pages 396-407 (October 2012) DOI: 10.1016/j.chom.2012.09.008 Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 1 Structure and Antibody Recognition of the HIV Envelope Spike The molecule is a heterotrimer of composition (gp120)3 (gp41)3. Gp41 is a transmembrane protein, and gp120 is the receptor molecule for CD4 and CCR5 (or CXCR4). The model (Schief et al., 2009) is adapted from a cryo-electron tomographic structure of the HIV trimer (Liu et al., 2008). The crystal structure of the b12-bound monomeric gp120 core (red) has been fitted into the density map (Zhou et al., 2007). Glycans are shown in purple. The CD4 binding site is shown in yellow. The approximate locations of the epitopes targeted by existing bnMAbs are indicated with arrows, and the number of MAbs targeting each epitope is shown in red boxes. A small selection of bnMAbs targeting each epitope is included. Cell Host & Microbe 2012 12, 396-407DOI: (10.1016/j.chom.2012.09.008) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 2 The Evolving Definition of Broad and Potent Neutralization of HIV For a long period, MAbs such as b12, 2G12, and 4E10 were the most potent and the most broadly available. MAbs PG9 (Walker et al., 2009) and VRC01 (Wu et al., 2010) were discovered and shown to be broad and about an order of magnitude more potent. Later, MAbs PGT121 and PGT128 (Walker et al., 2011a) were shown to be even more potent. The engineered mAb NIH45-46G54W is still more potent and broad (Diskin et al., 2011). Enhanced neutralization potency, if translated into enhanced protective ability, is important, since it reduces the level of antibody that should be induced by a vaccine. Cell Host & Microbe 2012 12, 396-407DOI: (10.1016/j.chom.2012.09.008) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 3 Model for Native Env Glycosylation Following removal of terminal α-linked glucose residues in the endoplasmic reticulum (ER), folded glycoproteins contain exclusively oligomannose glycans. During transit through the ER, intermediate compartment, and cis-Golgi apparatus, Manα1-2Man termini are removed by mannosidases to yield Man5GlcNAc2. However, the oligomannose cluster intrinsic to monomeric gp120 limits glycan processing on both monomeric and oligomeric gp120. The steric consequences of trimerization further limit Manα1-2Man trimming, leading to an additional “trimer-associated” population of Man5–9GlcNAc2. The exposed Man5GlcNAc2 glycans on gp120 that passage through the full extent of the Golgi apparatus and trans-Golgi network to the plasma membrane are processed to form complex-type glycans. However, envelope glycoprotein that does not follow this route to the plasma membrane—a notable feature of some pseudoviral production systems—is characterized by an elevated abundance of Man5GlcNAc2 and reduced furin cleavage (Crooks et al., 2011). Thus the intrinsic mannose patch, which includes the 2G12 epitope, persists from the earliest stages of glycan processing, while other elements of the glycan shield exhibit variably processed glycans depending on oligomerization state and, at least in the case of pseudoviral gp160/gp120, cellular trafficking (adapted from Bonomelli et al., 2011). Cell Host & Microbe 2012 12, 396-407DOI: (10.1016/j.chom.2012.09.008) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 4 T Follicular Helper Cells Are the CD4+ T Cells that Are Required for Germinal Centers and Control B Cell Differentiation within the GCs Tfh cells provide different signals to B cells to control different B cell fates, such as plasma cell (antibody secreting cell) differentiation, memory B cell differentiation, death, or repeated rounds of somatic hypermutation and GC B cell proliferation. Generation of high-affinity neutralizing antibodies is generally a multistep, iterative process that is dependent on affinity maturation via somatic hypermutation and extensive signaling from Tfh cells (Crotty, 2011). Cell Host & Microbe 2012 12, 396-407DOI: (10.1016/j.chom.2012.09.008) Copyright © 2012 Elsevier Inc. Terms and Conditions

Figure 5 An Approach to HIV Vaccine Discovery Molecular data on protective Abs (typically bnAbs), Env, and Ab-Env complexes, should facilitate the generation of antigens presenting protective epitopes. These antigens can then be formulated as immunogens and tested in animals and humans. The characteristics of the protective Abs also provide information on how they were generated that can be investigated in B and CD4+ T cell studies, guiding both immunogen design and immunization strategies. Gaps in our current knowledge suggest that iteration will be an important part of the development of vaccine candidates, as indicated by the feedback loops shown in the figure. Cell Host & Microbe 2012 12, 396-407DOI: (10.1016/j.chom.2012.09.008) Copyright © 2012 Elsevier Inc. Terms and Conditions